Romark Laboratories

Romark Laboratories is a pharmaceutical company committed to the discovery, development and commercialization of innovative small molecules for treating infectious diseases and cancers. Romark uses a proprietary technology platform to discover small molecules targeting cell signaling pathways. This research has led to the discovery of a new class of drugs called the thiazolides. The first thiazolide, nitazoxanide, is already commercialized in the United States as the well known drug Alinia. Romark has seen impressive growth since its founding in 1994 in Tampa, Florida. Romark most recently made headlines with it’s 2014 announcement of a new $110 Million dollar state-of-the-art pharmaceutical plant and operation’s arm in Puerto Rico.

Scalio architected, designed, and developed a Private Investor Platform that allows Romark’s team to manage their investors and accounts, while simultaneously rewarding Romark’s investors for their continued dedication. The web app serves as a platform for investors and brokers alike to view account statements, execute e-file documents, keep up with the latest news at Romark, and much more. Scalio also built an admin portal with extensive reporting, emailing, multimedia, and e-filing capabilites.